Odessa
Well-known member
Abstract from the paper I gave the link to the second link
39
The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of
40
concern (VOC) break through infection- or vaccine-induced immunity is not well understood. Here,
41
we analyze 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status
42
obtained through national community testing in the Netherlands from March to August 2021. We
43
find evidence for an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta
44
(B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences
45
were found between vaccines. However, the effect was larger in the first 14-59 days after complete
46
vaccination compared to 60 days and longer. In contrast to vaccine-induced immunity, no increased
47
risk for reinfection with Beta, Gamma or Delta variants relative to Alpha variant was found in
48
individuals with infection-induced immunity.
39
The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of
40
concern (VOC) break through infection- or vaccine-induced immunity is not well understood. Here,
41
we analyze 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status
42
obtained through national community testing in the Netherlands from March to August 2021. We
43
find evidence for an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta
44
(B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences
45
were found between vaccines. However, the effect was larger in the first 14-59 days after complete
46
vaccination compared to 60 days and longer. In contrast to vaccine-induced immunity, no increased
47
risk for reinfection with Beta, Gamma or Delta variants relative to Alpha variant was found in
48
individuals with infection-induced immunity.